ParinGenix Inc., a Charlotte, N.C.-based developer of multiple drugs based on a modified form of heparin, has secured $5.92 million of a $20.4 million Series B round, according to a regulatory filing. Shareholders include Academy Venture Funds, Research Corporation Technologies Inc. and A.P. Kennedy Family Securities. ParinGenix was a presenter at the SEBIO Investor Forum 2005 in Charleston, SC. www.paringenix.com